# Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

> **NCT07637513** · PHASE3 · NOT_YET_RECRUITING · sponsor: **PrECOG, LLC.** · enrollment: 430 (estimated)

## Conditions studied

- Limited Stage Small-Cell Lung Cancer

## Interventions

- **DRUG:** Tarlatamab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT07637513
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2037-11
- **Final completion:** 2038-06
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2026-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637513, "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*